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OBJECTIVE — The purpose of this study was to investigate whether adiponectin concentra-
tions and biomarkers of inﬂammation, endothelial dysfunction, and insulin resistance mediate
the association between alcohol consumption and diabetes.
RESEARCHDESIGNANDMETHODS — Inanestedcase-controlstudyof705women
withincidentdiabetesand787matchedcontrolsubjects,weexaminedtheadjustedrelationship
between baseline alcohol consumption and risk of diabetes before and after adjustment for
markers of inﬂammation/endothelial dysfunction (C-reactive protein, vascular cell adhesion
molecule-1, intercellular adhesion molecule-1, E-selectin, tumor necrosis factor- receptor 2,
and interleukin-6), fasting insulin, and adiponectin concentrations.
RESULTS — Alcohol consumption was associated with a decreased risk of diabetes (odds
ratio per 12.5 g/day increment in alcohol use 0.58; 95% CI 0.49–0.69; P  0.001). Adjustment
for BMI attenuated the association by 25%. None of the markers of inﬂammation or fasting
insulinappearedtoaccountfor2%oftheobservedrelationship.WithoutadjustmentforBMI,
these biomarkers individually explained slightly more of the association, but 10% in all cases.
Adiponectin accounted for 25% in a fully adjusted model and for 29% without adjustment
for BMI.
CONCLUSIONS — In this population of women, alcohol consumption was inversely asso-
ciatedwithriskoftype2diabetes.Adiponectinappearedtobeamediatorofthisassociation,but
circulating biomarkers of inﬂammation, endothelial dysfunction, and fasting insulin did not
explain this association. These results suggest that further research is needed into the potentially
mediating roles of other biomarkers affected by alcohol consumption.
Diabetes Care 31:2050–2055, 2008
M
oderate alcohol consumption is
associatedwithadecreasedriskof
both coronary heart disease and
type 2 diabetes compared with abstaining
and heavier drinking (1,2). Approxi-
mately 50% of the association with coro-
nary heart disease (CHD) appears to be
attributable to an increase in HDL choles-
terol (3), and ﬁbrinogen and glycemia
mayaccountforalargepartoftheremain-
der (4).
The underlying mechanism for the
lower risk of type 2 diabetes among mod-
erate drinkers is not entirely clear, but
several factors may be involved. First,
high concentrations of markers of both
inﬂammation and endothelial dysfunc-
tion are directly related to risk of type 2
diabetes(5,6),andmoderatealcoholcon-
sumption is associated with lower levels
of markers of inﬂammation and endothe-
lial dysfunction in both cross-sectional
and intervention studies (7,8). Second, a
randomizedcontrolledtrial(9)andcross-
sectional studies (10) have shown im-
proved insulin sensitivity with moderate
alcohol consumption, but results of stud-
ies are not entirely consistent (11). These
changes in insulin sensitivity could be
mediated by an increase in adiponectin
concentrations that has been consistently
shown in several observational and ran-
domized studies (11,12). Finally, BMI is
the most important predictor of type 2
diabetes, particularly among women
(13). Cross-sectional studies and a recent
prospective study suggest that moderate
alcohol consumption may be associated
with lower BMI and less weight gain over
time among women but not men (14,15).
Whether and to what extent markers
ofinﬂammation,endothelialdysfunction,
fasting insulin, and adiponectin concen-
trations explain the inverse association
between moderate alcohol consumption
and type 2 diabetes has not been investi-
gated to date. To address these questions,
we investigated these relations in a nested
case-control study from the Nurses’
Health Study. Previous reports from this
study have shown that moderate alcohol
consumption,BMI,markersofinﬂamma-
tion and endothelial dysfunction, and
fasting insulin are all associated with the
risk of type 2 diabetes (5,6) in expected
directions.
RESEARCH DESIGN AND
METHODS— The Nurses’ Health
Study began in 1976, when 121,700 fe-
male nurses aged 30–55 years responded
to a questionnaire of health-related infor-
mation. Questionnaires have been ad-
ministered biennially to update health
informationandidentifynewcasesofdis-
ease. During 1989–1990, 32,826 women
freeofdiagnoseddiabetes,coronaryheart
disease, stroke, or cancer provided blood
samples. Women providing blood sam-
ples had a higher prevalence of obesity
and family history of diabetes and a lower
prevalence of current smoking but were
otherwisesimilartowomennotproviding
blood. By 2000, 714 of these women had
a conﬁrmed diagnosis of type 2 diabetes.
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the
Netherlands; the
2Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts; the
3Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; the
4Channing Lab-
oratory, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston,
Massachusetts;
5Business Unit Biosciences, TNO Quality of Life, Zeist, the Netherlands; and the
6Division of
General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Corresponding author: Joline W.J. Beulens, j.beulens@umcutrecht.nl.
Received 29 April 2008 and accepted 10 July 2008.
Published ahead of print at http://care.diabetesjournals.org on 15 July 2008. DOI: 10.2337/dc08-0814.
© 2008 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cardiovascular and Metabolic Risk
ORIGINAL ARTICLE
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were matched to diabetes case patients by
year of birth, date of blood draw, race,
and fasting status at blood draw. From
1990 until 1996, two control subjects
were matched to each case patient on the
basis of the above factors. One of the two
controlsubjectswasalsomatchedaccord-
ing to BMI within 1 kg/m
2. After 1996,
one control subject was matched to each
case patient on the basis of the same char-
acteristics, and another control subject
was matched on these characteristics and
BMI to each of the case patients in the top
decile of the BMI distribution. Women
withmissinginformationforalcoholcon-
sumption and markers of inﬂammation
and endothelial dysfunction were ex-
cluded, leaving 787 control subjects and
705 case patients for analysis.
Subjects provided written informed
consent. The studies were approved by
the institutional review board of Partners
HealthCare System, Boston, MA.
Ascertainment of diabetes
Incident cases of type 2 diabetes were
identiﬁedbyself-reportandconﬁrmedby
a validated supplementary questionnaire
detailing symptoms, diagnostic labora-
tory test results, and diabetes treatment.
The diagnosis was conﬁrmed if partici-
pants reported at least one of the follow-
ing on the questionnaire: treatment with
either insulin or an oral hypoglycemic
agent, at least one classic symptom of di-
abetes (for instance, polyuria, polydipsia,
or weight loss) plus an elevated plasma
glucose level, or an elevated plasma glu-
cose level on at least two occasions in the
absence of symptoms. Elevated plasma
glucose was deﬁned as at least 140 mg/dl
(7.8 mmol/l) fasting, or at least 200
mg/dl (11.1 mmol/l) nonfasting, or at
least 200 mg/dl (11.1 mmol/l) at 2h
after an oral glucose tolerance test for
cases diagnosed before 1998; for cases di-
agnosed in 1998 and later, the fasting
plasma glucose threshold was lowered to
126 mg/dl (7.0 mmol/l). The validity
of self-reported diabetes has been con-
ﬁrmed with medical record review in a
sample of 62 participants.
Assessment of alcohol consumption
We assessed average alcohol consump-
tion within a semiquantitative food fre-
quency questionnaire including separate
items for beer, white wine, red wine, and
liquor (16). We speciﬁed standard por-
tions as a glass, bottle, or can of beer; a
4-ounce glass of wine; and a shot of li-
quor.Foreachbeverageparticipantswere
asked to estimate their average consump-
tionoverthepastyear.Wecalculatedeth-
anol intake by multiplying the frequency
of consumption of each beverage by the
alcohol content of the speciﬁed portion
size (12.8 g for beer, 11.0 g for wine, and
14.0 g for liquor) and summing across
beverages. We used alcohol consumption
reported on the food frequency question-
naire in 1990 and replaced information
with data from 1986 onward when miss-
ing data occurred.
Wepreviouslyassessedthevalidityof
alcohol consumption estimated with the
food frequency questionnaire against in-
takefromtwo1-weekdietaryrecordscol-
lected 6 months apart among 173
womenresidingineasternMassachusetts;
the Spearman correlation coefﬁcient be-
tween these two measures was 0.90. Esti-
mated average alcohol intake was also
correlated with HDL cholesterol to an
expected degree (r  0.40), and HDL
cholesterol levels among drinkers were
15–20% higher than those among
nondrinkers (17).
Assessment of lifestyle factors
Lifestylefactorswereassessedusingques-
tionnaires, including smoking, body
weight, physical activity, family history of
diabetes, menopausal status, and use or
nonuse of postmenopausal hormone
therapy. Reported weights have been
shown to correlate well with measured
weights (r  0.96), and the assessment of
physicalactivitywaspreviouslyvalidated.
We obtained energy intake, glycemic
load, coffee consumption, and energy-
adjusted intakes of saturated fat, trans
fatty acids, polyunsaturated fatty acids,
and dietary ﬁber from the semiquantita-
tive food frequency questionnaire (16).
Laboratory procedures
Women were sent a phlebotomy kit with
instructions to return the sample by over-
night mail with a frozen water bottle. On
arrival, samples were processed and fro-
zen in liquid nitrogen until analysis; 97%
arrived within 26 h of phlebotomy. Qual-
ity control samples were routinely frozen
with study samples; the long-term stabil-
ityofplasmasamplescollectedandstored
under this protocol has been docu-
mented. Study samples were analyzed in
randomly ordered case-control pairs to
further reduce systematic bias and inter-
assay variation.
Levels of E-selectin, intercellular ad-
hesion molecule-1 (ICAM-1), and vascu-
lar cell adhesion molecule-1 (VCAM-1)
were measured by a commercial enzyme-
linked immunosorbent assay (ELISA)
(R&D Systems, Minneapolis, MN). These
biomarkers are released during endothe-
lial cell activation and correlate (r 
0.04–0.58) with endothelial dysfunction
assessed directly by brachial artery ﬂow-
mediated vasodilatation or microcircula-
tion iontophoresis methods (18).
C-reactiveprotein(CRP)levelsweremea-
sured via a high-sensitivity latex-
enhanced immunonephelometric assay
(Dade Behring, Newark, DE). Interleu-
kin-6 (IL-6) was measured by a quantita-
tive sandwich enzyme immunoassay
technique (Quantikine HS Immunoassay
kit),andtumornecrosisfactor-receptor
2 (TNF-R2) levels were measured by an
ELISA kit using immobilized monoclonal
antibody to human TNF-R2 (Genzyme,
Cambridge, MA). Insulin levels were
measuredusingadoubleantibodysystem
with 0.2% cross-reactivity between in-
sulin and its precursors (Linco Research,
St. Louis, MO). C-peptide was measured
usingantiserumM1230inanalcoholpre-
cipitation nonequilibrium assay. In the
C-peptide assay, proinsulin has 10%
cross-reactivity, but its contribution to C-
peptideimmunoreactivityis0.5%.Pro-
insulin-like material was measured using
antiserum 11E in a nonequilibrium assay
with second-antibody precipitation. In
the proinsulin assay, human proinsulin
cross-reacts 100%, des-31,32 proinsulin
cross-reacts38%,anddes-64,65proinsu-
lin cross reacts 10%, whereas insulin and
C-peptide each cross-react 0.001%.
The coefﬁcients of variation were 3.8%
forCRP,5.9%forIL-6,6.2%forTNF-R2,
6.6% for E-selectin, 3.6% for ICAM-1,
8.5–9.8% for VCAM-1, 3.5–11.7% for
fasting insulin, 1.9–3.0% for A1C, 2–7%
for C-peptide, and 6–9% for proinsulin.
Adiponectin was determined by ELISA
(ALPCO Diagnostics, Salem, NH). The
sensitivity of this assay is 0.04 ng/ml, and
the recovery rate was 99–103%.
Statistical analysis
Analyses were performed in three sepa-
rate groups that had valid information on
a speciﬁc set of potential mediating bio-
markers: the main dataset for markers of
inﬂammation and endothelial dysfunc-
tion (case patients 705; control subjects
787) and three additional sets for fasting
insulin (case patients 476; control sub-
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tions (case patients 694; control subjects
982). In the main dataset individual
markers of inﬂammation and endothelial
dysfunction were missing for no more
than 4% of the sample. To maintain con-
sistent sample sizes across markers, these
missing values were imputed using the
median of the sample. An inﬂammation
score was created by summing the quar-
tilesofCRP,IL-6,E-selectin,andTNF-R2
to assess their combined effect.
We examined the relationships of al-
cohol consumption, biomarkers, and risk
of type 2 diabetes with a three-step pro-
cess. First, we estimated the independent
association of alcohol consumption with
riskusingmultivariableunconditionallo-
gistic regression models. In these models,
we adjusted for matching and confound-
ingfactors,includingBMI(quintiles),and
for smoking (never, former, or current
smokers of 1–14, 15–34, or 35 ciga-
rettes/day), family history of diabetes in a
ﬁrst-degree relative (present or not),
physical activity (ﬁve categories), post-
menopausal hormone therapy (premeno-
pausal, never, past, or current user),
energy intake, coffee consumption, and
energy-adjusted intakes of saturated fat,
trans fatty acids, polyunsaturated fatty ac-
ids, glycemic load, and dietary ﬁber (each
in quintiles).
Second, we added biomarkers to the
model(as linearterms)toassesstheper-
cent change of the -coefﬁcient (the log
of the odds ratio [OR]) for alcohol con-
sumption; these coefﬁcients are scaled
linearly. Inclusion of a mediating factor
would be expected to attenuate the
-coefﬁcient related to alcohol intake.
Third, because BMI could act as both a
confounder and a mediator of the effects
of alcohol on diabetes (i.e., obesity could
affect alcohol consumption and vice
versa), we repeated our analyses without
BMI in the model and examined the me-
diating contributions of both BMI and in-
dividual biomarkers.
In all analyses, we modeled alcohol
consumption as a linear term in incre-
ments of 12.5 g (1 drink) per day. In-
clusion of a quadratic term revealed no
evidence of a nonlinear relation. We
also modeled alcohol consumption on
the log scale, which had maximum
model ﬁt, with similar results; for ease
of interpretation, those results are not
shown. Analyses were performed using
the SAS statistical package (version 8.2;
SAS Institute, Cary, NC).
RESULTS— Baselinecharacteristicsof
the case patients and control subjects are
shown in Table 1. Women who devel-
oped type 2 diabetes had higher BMI,
family history of diabetes, and intake of
saturated and trans fatty acids and mark-
ers of inﬂammation, endothelial dysfunc-
tion, and fasting insulin than control
subjects. Alcohol and coffee consump-
tion, physical activity, and adiponectin
concentrationswereloweramongwomen
who developed type 2 diabetes than
among control subjects. Of our study
population,640womendidnotconsume
alcohol, 706 consumed 0–12.5 g/day, 88
consumed 12.5–25 g/day, 45 consumed
25–37.5 g/day, 7 consumed 37.5–50
g/day,1consumed50–62.5g/day,4con-
sumed 62.5–75 g/day, and 1 consumed
100 g/day. All mediating biomarkers
were signiﬁcantly correlated with alcohol
consumption in expected directions (Ta-
ble 2).
Mediating biomarkers
Table 3 shows the association between al-
cohol consumption (modeled per 12.5-g
increment)andriskoftype2diabetesand
theextenttowhichmediatingbiomarkers
explained this association. Alcohol con-
sumptionwasassociatedwithadecreased
risk of type 2 diabetes in this sample of
women with an OR of 0.58 (95% CI
0.49–0.69)per12.5-gincrementofalco-
hol intake (P  0.001), adjusted for
matching and confounding factors. Fur-
ther adjusting this estimate for BMI atten-
uated the -coefﬁcient for alcohol intake
by 25%.
None of the markers of inﬂammation
and endothelial dysfunction appeared to
explain 2% of the association of alcohol
consumption with diabetes. Without ad-
justment for BMI, these percentages in-
creased but were never 10%, although
inclusion of CRP attenuated the risk esti-
mate by 9%. Combining CRP, IL-6, E-
selectin, and TNF-R2 in an inﬂammation
score, they accounted for 8% of the asso-
Table 1—Descriptive characteristics of control women and women who developed type 2
diabetes
Control subjects Case patients P
n 787 705
Age (years) 56.7  6.9 56.8  6.8 NS
BMI (kg/m
2) 26.4  6.1 30.4  5.6 0.001
Physical activity (METs/week) 15.6  27.1 12.1  14.7 0.002
Alcohol consumption (g/day) 1.8 (0–6.9) 0 (0–2.7) 0.001
Smoking (%)
Never 46.0 43.7 NS
Past 41.4 42.8 NS
Current 12.6 13.5 NS
Family history of diabetes (%) 20.1 44.8 0.001
Postmenopausal (%) 78.5 81.1 NS
Nutrients*
Energy (kcal) 1769  512 1817  561 NS
Saturated fatty acids (g) 20.9  8.4 22.4  9.3 0.002
Trans fatty acids (g) 3.0  1.5 3.2  1.6 0.005
Polyunsaturated fatty acids (g) 11.7  5.1 12.1  5.0 NS
Fiber (g) 19.9  8.0 20.0  8.3 NS
Glycemic load 117.4  41.9 120.8  44.8 NS
Coffee consumption (cups/day) 2.2  1.8 2.0  1.7 0.03
Biomarkers
Insulin (U/ml) 7.5 (4.2–11.0) 11.2 (7.1–17.1) 0.001
CRP (mg/dl) 0.16 (0.07–0.35) 0.37 (0.20–0.63) 0.001
VCAM-1 (ng/ml) 526.0 (444.0–614.2) 545.1 (458.8–646.8) 0.003
ICAM-1 (ng/ml) 247.3 (218.1–277.4) 264.5 (233.2–316.9) 0.001
E-selectin (ng/ml) 45.4 (33.8–60.1) 61.5 (45.4–80.6) 0.001
TNF-R2 (pg/ml) 2396 (2,013–2,861) 2638 (2,209–3,158) 0.001
IL-6 (ng/ml) 1.8 (1.2–2.7) 2.4 (1.7–3.5) 0.001
Adiponectin (g/ml) 17.7 (12.2–22.6) 10.1 (6.8–15.1) 0.001
Data are means  SD or median (interquartile range) if not normally distributed. *All nutrients are energy
adjusted except energy.
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17% without adjustment for BMI. Ex-
cludingwomenwithclinicallyrelevantel-
evations of CRP (n  128) did not
essentially change our results but only
slightly increased the percentage ex-
plained for some markers. For example,
CRP now explained 12% in a model un-
adjusted for BMI.
Adiponectin explained the associa-
tion between alcohol consumption and
type 2 diabetes by 25% in a fully adjusted
model and by 29% without adjustment
for BMI. Fasting insulin did not appear to
explain the association between alcohol
consumption and type 2 diabetes. With-
out adjustment for BMI, inclusion of fast-
ing insulin attenuated the observed
estimate for alcohol by 7%. In sensitivity
analyses, fasting concentrations of proin-
sulin and C-peptide did not attenuate the
association either (data not shown).
Including BMI as a continuous vari-
ableinourmodelsdidnotaltertheresults
of this study (data not shown). Excluding
women consuming 50 g alcohol/day
did not affect our results.
CONCLUSIONS— In this study, we
aimed to quantify the extent to which
markers of inﬂammation, endothelial
dysfunction, fasting insulin, and adi-
ponectin could explain the lower risk of
type 2 diabetes associated with moderate
alcohol consumption. Only adiponectin
explained this relation by 25–30%.
None of the other markers, however, ap-
peared to explain this association to any
large extent. This ﬁnding suggests that,
apart from adiponectin, other pathways
may be less important.
Itissurprisingthatmarkersofinﬂam-
mation and endothelial dysfunction did
not seem to play a role in the relationship
of alcohol consumption with risk of dia-
betes.Thiscontrastswithourpreviousre-
sults for CHD, for which inﬂammatory
markersappearedtoexplain20%ofthe
association (4). Two other studies, how-
ever, showed no substantially mediating
effect of inﬂammation on the association
of alcohol consumption with CHD
(19,20). Our results suggest that inﬂam-
mation and endothelial dysfunction may
have little role in the association between
alcoholconsumptionandtype2diabetes.
Rather, inﬂammation and endothelial
dysfunction may be indirectly related to
type 2 diabetes via associations with BMI
(21). Indeed, they were stronger interme-
diates in this study when BMI was not
included as a covariate.
The effect of moderate alcohol con-
sumption on insulin sensitivity is not
completely understood. Randomized
controlled trials and cross-sectional stud-
ies have not always reported consistent
results (9–11). Of note, the longest and
largest study did ﬁnd a dose-dependent
effect of alcohol consumption on insulin
sensitivity and fasting insulin in post-
menopausal women similar to our study
population. However, our ﬁndings sug-
gest that the risk reduction of type 2
diabetes with moderate alcohol con-
sumption is not simply due to improved
insulin sensitivity, at least as captured by
fasting insulin.
Recent studies have shown that mod-
erate alcohol consumption increases adi-
ponectin concentrations and its oli-
gomers (11), a ﬁnding conﬁrmed in
observational studies (12). Adiponectin
directlyimprovesinsulinsensitivityinan-
imal models. Indeed, we show here that
adiponectin is an important mediator of
the relation between alcohol consump-
tionandtype2diabetes.However,asadi-
ponectinonlyexplained25–30%ofthe
association,othermechanismsapartfrom
those described here need to be further
explored.
It is difﬁcult to assess whether the at-
tenuationofthealcohol-diabetesrelation-
ship by BMI reﬂects confounding by BMI
Table 2—Spearman correlations between alcohol consumption and mediating biomarkers
Biomarker n Spearman correlation (P)
CRP 1,467 	0.14 (0.001)
VCAM-1 1,491 	0.09 (0.001)
ICAM-1 1,489 	0.09 (0.001)
E-selectin 1,490 	0.10 (0.001)
IL-6 1,442 	0.07 (0.005)
TNF-R2 1,477 	0.13 (0.001)
Insulin 1,055 	0.11 (0.001)
Adiponectin 1,677 0.18 (0.001)
Table 3—Alcohol consumption (per 12.5 g/day), mediating biomarkers, and risk of type 2 diabetes among 787 control women and 705 women
who developed type 2 diabetes
BMI adjusted Not BMI adjusted
OR (95% CI)  coefﬁcient % Attenuated OR (95% CI)  coefﬁcient % Attenuated
MV adjusted* 0.67 (0.56–0.79) 	0.41  0.09 — 0.58 (0.49–0.69) 	0.55  0.09
BMI NA NA NA 0.67 (0.56–0.79) 	0.41  0.09 25
CRP 0.67 (0.56–0.80) 	0.41  0.09 0 0.61 (0.51–0.72) 	0.50  0.09 9
VCAM-1 0.67 (0.56–0.80) 	0.40  0.09 1 0.59 (0.50–0.69) 	0.54  0.09 2
ICAM-1 0.67 (0.56–0.80) 	0.40  0.09 1 0.59 (0.49–0.69) 	0.54  0.09 2
E-selectin 0.67 (0.56–0.80) 	0.41  0.09 	1 0.59 (0.50–0.71) 	0.52  0.09 5
IL-6 0.67 (0.57–0.80) 	0.40  0.09 2 0.59 (0.50–0.70) 	0.53  0.09 3
TNF-R2 0.67 (0.56–0.80) 	0.40  0.09 1 0.60 (0.50–0.70) 	0.52  0.09 5
MV adjusted* 0.71 (0.59–0.87) 	0.34  0.10 0.65 (0.53–0.79) 	0.44  0.10
Insulin 0.71 (0.58–0.87) 	0.34  0.10 0 0.67 (0.55–0.82) 	0.41  0.10 7
MV adjusted* 0.71 (0.61–0.83) 	0.35  0.08 0.66 (0.56–0.77) 	0.42  0.08
Adiponectin 0.77 (0.65–0.91) 	0.27  0.08 24 0.74 (0.63–0.87) 	0.30  0.08 29
*Multivariate(MV)modelsareadjustedforBMI,physicalactivity,smoking,familyhistoryofdiabetes,postmenopausalhormonereplacementtherapy,energyintake,
and energy-adjusted intake of saturated fat, trans fatty acids, polyunsaturated fat, dietary ﬁber, glycemic load, and coffee consumption. NA, not applicable.
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ing weight gain in women. A recent study
among 49,324 women showed that mod-
erate alcohol consumption was prospec-
tively associated with a decreased 8-year
weight gain, whereas heavier drinkers
hadanincreasedriskforweightgain(14).
Other studies among women have con-
ﬁrmed these results, whereas no or even a
positive association with body weight is
reported for men (15). To date, few pro-
spective randomized interventions exam-
ined the effect of moderate alcohol
consumption on body weight (9), but
these have not been long enough to ex-
clude such an effect conclusively.
The mechanisms underlying the pro-
tective effect of light to moderate alcohol
consumption are complex and not com-
pletely understood. Our results suggest
that other mechanisms apart from adi-
ponectin explain the association between
alcoholconsumptionandtype2diabetes.
Lipotoxicity, excess release of free fatty
acidsfromadiposetissue,isthoughttobe
an important cause of insulin resistance.
In the liver, free fatty acids increase glu-
cose production, triglycerides, and secre-
tion of VLDL. Associated lipoprotein
abnormalities include reductions in HDL
andincreasedLDL.Alcoholconsumption
stronglyaffectslipidmetabolism(22)and
could thereby possibly also inﬂuence in-
sulin resistance and risk of type 2 diabe-
tes. Another possibility is that the effects
of moderate drinking are not related to
ethanolitselfbuttoacetate,theendprod-
uctofethanoloxidation(23).Acetatemay
affect fat oxidation and decrease lipolysis
andfreefattyacidsandindirectlyimprove
insulin sensitivity (24).
The strengths of this study include its
prospective design; detailed assessment
of alcohol consumption, diet, and life-
style;andinclusionofavarietyofmarkers
previously related to risk of diabetes.
Nonetheless, certain limitations need to
be addressed. Because insulin was only
assessedforthosewithfastingbloodsam-
ples, we used slightly different subgroups
for each group of biomarkers, which may
have introduced some selection bias.
However, within each subgroup, moder-
ate alcohol consumption was associated
withasimilardecreasedriskofdiabetesas
in the entire case-control study. In addi-
tion, we could only include women pro-
viding blood samples in this study, which
couldalsobesubjecttoselection.Incom-
paring those women with women not
providingbloodsamples,theyhadhigher
prevalences of obesity and family history
ofdiabetes,whichcouldleadtoincreased
diabetesriskinthissample.However,be-
cause we only included incident cases of
diabetes, selection of these women is not
related to the occurrence of disease and
thereforedoesnotleadtoselectionbias.It
could limit generalizability of our results
to women with a slightly lower diabetes
risk.
We were restricted to fasting insulin
as a measure of insulin sensitivity, but it
only correlates modestly to the hyperin-
sulinemic-euglycemic clamp technique.
Other studies using more robust markers
of insulin sensitivity such as homeostasis
model assessment are needed to deter-
mine the full degree to which insulin sen-
sitivity mediates the association between
alcohol consumption and diabetes. Other
biomarkers such as adiponectin, which
could potentially mediate a substantial
part of the association, should be in-
cluded in such studies as well.
In summary, adiponectin explains
about 25–30% of the relation between al-
cohol consumption and type 2 diabetes.
Markers of inﬂammation, endothelial dys-
function, and fasting insulin did not appear
to play an important role. These results
cast some doubt on the physiological im-
portance of the effects of alcohol on inﬂam-
mationandendothelialfunction,atleastfor
glucose metabolism, and suggest that fur-
ther research is needed into the potentially
mediating roles of other biomarkers af-
fected by alcohol consumption.
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